DOCSLIB.ORG

Ten Warning Signs of Primary Immunodeficiency

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ten Warning Signs of Primary Immunodeficiency Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: The Year in Human and Medical Genetics: Inborn Errors of Immunity Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century Peter D. Arkwright1 and Andrew R. Gennery2 1Department of Paediatric Allergy and Immunology, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom. 2Department of Paediatric Immunology, University of Newcastle upon Tyne, Newcastle, United Kingdom Address for correspondence: Peter D. Arkwright, Senior Lecturer in Paediatric Immunology, Department of Paediatric Allergy and Immunology, Royal Manchester Children’s Hospital, Oxford Road, Manchester M13 9WL. [email protected] The 10 warning signs of primary immunodeficiency are being promoted as a screening tool for use by both the general public and physicians. A recent study, however, shows that except for family history, need for intravenous antibiotics and failure to thrive, the 10 warning signs are not a useful screen of primary immunodeficiency diseases (PIDs). Over the last few decades, there has been a revolution in our understanding of PID. The 10 warning signs do not take into account the fact that PIDs now include diseases that present with sporadic infections, autoimmunity, autoinflammation, and malignancy. This review focuses on the advances in our understanding of PID, the current limitations of the 10 warning signs, and recommendations to ensure that patients with PID are diagnosed in a timely fashion in the future. Keywords: primary immunodeficiency; autoimmunity; atopic dermatitis; cancer; family history Preferred citation: Arkwright, P.D. & A.R. Gennery. 2011. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century. In “The Year in Human and Medical Genetics: Inborn Errors of Immunity I.” Jean-Laurent Casanova, Mary Ellen Conley & Luigi Notarangelo, Eds. Ann. N.Y. Acad. Sci. 1238: 7–14. First studies characterizing primary serious, recurrent, or unusual infections. Changes to immunodeficiency diseases the way we promote awareness of PID among the medical profession and sectors of the general public The first primary immunodeficiency diseases are required if premature death and serious mor- (PIDs) were identified 50–60 years ago, at a time bidity due to late diagnosis of the wider spectrum when immunoglobulin was first measured and iso- , of PID are to be avoided. lated from serum1 2 and the function of lymphocytes as an important component of the immune system 3 The development of the 10 warning signs was recognized. The earliest PID to be described of primary immunodeficiency included disorders of neutrophils (chronic gran- ulomatous disease),4 Tlymphocytes(severecom- The first PIDs to be discovered were manifest by bined immunodeficiency [“Swiss-type”]),5 Wiskott a propensity to recurrent severe or unusual infec- Aldrich syndrome,6 and B lymphocytes (Bruton’s tions. Attending physicians learned to recognize agammaglobulinemia).7 Along with this expan- patterns of clinical disease that suggested the pa- sion in our understanding of the immune basis of tient may have an underlying primary immune PID, new therapies were being developed, including defect.9–11 Over the last few decades, the number the introduction of immunoglobulin replacement of clinicians and scientists involved in the diag- (1952) and bone marrow transplantation (1957).8 nosis and management of PID has expanded ex- The molecular etiology of 150 different PIDs have ponentially, initially in western Europe (European now been defined. The spectrum of clinical presen- Society for Immunodeficiencies) and the United tations of PID is now recognized to include autoin- States (United States Immunodeficiency Network; flammation, autoimmunity, and neoplasia as well as http://www.usidnet.org/), and more recently in doi: 10.1111/j.1749-6632.2011.06206.x Ann. N.Y. Acad. Sci. 1238 (2011) 7–14 c 2011 New York Academy of Sciences. 7 Ten warning signs of PID in the 21st century Arkwright & Gennery eastern Europe (J Project),12 the Middle East Table 1. Ten warning signs of primary immunodeficiency (Asian Society for Primary Immunodeficiency), ≥ northern Africa (African Society for Immunode- 1 4 ear infections in one year ≥ ficiency), South America (Latin American Group 2 2 serious sinus infections in one year ≥ for Primary Immunodeficiencies), and other parts 3 2 pneumonias in one year of the world. Better training of physicians has led to 4 Recurrent, deep skin or organ abscesses diagnosis of more patients with PID.13 The preva- 5 Persistent thrush in mouth or fungal lence of PID is currently estimated to be 1/10,000 infection on skin ≥ people in the Western world. 6 2 deep-seated infections including A number of nonprofit organizations (Jeffery septicemia ≥ Modell Foundation, International Patient Organ- 7 2 months on antibiotics with little isation for Primary Immunodeficiencies, Primary effect Immunodeficiency Association) provide valuable 8 Need for intravenous antibiotics to clear support for families with PID as well as health infections care professionals looking after these patients. Re- 9 Failure of an infant to gain weight or cently, these organizations have become increas- grow normally ingly vocal in promoting public awareness of PID 10 Family history of primary at a government level as well as among the gen- immunodeficiency eral public. The 10 warning signs of primary im- Note: If you or someone you know is affected by ≥2 munodeficiency, based largely on clinical presen- warning signs, speak to a physician about the possible tation of antibody immunodeficiencies in adults14 presence of an underlying primary immunodeficiency; and expert opinion, are now heavily promoted as www.info4pi.org/aboutPI/index.cfm?section=aboutPI& a way of making people aware of PID, most re- content=warningsigns, accessed July 18, 2011. cently through World Primary Immunodeficiency Week 2011 (www.worldpiweek.org/). The clinical was a family history, with use of intravenous antibi- features focus on the occurrence of recurrent upper otics for sepsis in children with neutrophil PID and and lower respiratory tract infections (sinus, ear, failure to thrive in children with T lymphocyte PID and chest), persistent superficial fungal infections, of secondary importance. Using these three signs, or more deep-seated infections (localized abscesses 96% of patients with neutrophil and complement or disseminated blood-borne infections). The need deficiencies and 89% of children with T lympho- for intravenous antibiotics or prolonged courses of cyte PID could be correctly identified. The results oral antibiotics, failure to thrive in infancy, and a indicated that as well as hospital physicians, educa- family history of PID are also included (Table 1). tion and particularly genetic counseling of families who have had a child with a PID are important. Validity of the 10 warning signs in The 10 warning signs leaflet advises that if two or predicting the likelihood of PID in children more warning signs are present, PID should be con- It remains the role of specialists who treat patients sidered. Wetherefore performed additional analyses with PID to ensure that promotional material is to determine whether two or more warning signs are accurate and up to date in relation to the rapid ad- more common in children with defined PID com- vances in the field of immunodeficiency. As the ef- pared with those where no PID is found. Two or fectiveness of the 10 warning signs as a screening test more warning signs identified children with neu- of PID had not previously been formally assessed, trophil PID but not those with complement, B cell early in 2011 we evaluated the presenting symptoms or T cell PID (Table 2). of 563 children attending two tertiary pediatric im- Evolving concepts of infectious diseases munology centers in the north of England.15 Ninety- that may herald PID six percent of the children with PID were referred by hospital clinicians, indicating that the most im- It is now recognized that PID may not only present portant group to target regarding awareness and with recurrent or unusual infections, but that one- education of PID are hospital doctors who are most off infections with common pathogens may also her- likely to be called on to manage children at presen- ald a life-threatening PID. To delay considering the tation. The strongest identifier of PID in our study diagnosis of PID for the appearance of subsequent 8 Ann. N.Y. Acad. Sci. 1238 (2011) 7–14 c 2011 New York Academy of Sciences. Arkwright & Gennery Ten warning signs of PID in the 21st century Table 2. Frequency (percentage) of ≥2 warning signs in cytosis, hereditary angioedema, immunodysregu- children with and without PID lation polyendocrinopathy enteropathy X-linked [IPEX], IL-10 receptor deficiency, and periodic fever Relative risk syndromes). Thus, in our north of England cohort, (95% CI) at least one in five patients with PID would be missed < ≥ 2 Warning 2 Warning compared if the 10 warning signs were used as a screen. signs signs with no PID To illustrate this point further, a classic exam- ple of a PID disease, where presentation is usu- No PID 70 (52%) 63 (48%) – ∗ ally with noninfectious features, is IPEX syndrome Any PID 163 (38%) 267 (62%) 1.8 (1.2–2.7) ∗ due to mutations in the FOXP3 gene. IPEX is due Neutrophil 10 (14%) 63 (86%) 7.0 (3.3–14) to a deficiency of T regulatory cells, and children PID present with severe, often unremitting autoimmune Complement 9 (41%) 13 (59%) 1.6 (0.6–4.0) enteropathy, endocrinopathies, such as thyroid dis- PID ease and diabetes mellitus, autoimmune cytopenias, B cell PID 42 (40%) 63 (60%) 1.7 (1.0–2.8) and eczema. Recurrent infections may or may not T cell PID 102 (44%) 128 (56%) 1.4 (0.9–2.1) occur as part of the clinical course.24 Even some ∗Significant at P < 0.01 by Chi-square, compared with of the earliest PIDs to be described, for example the group that did not have a PID.
Load more

Recommended publications
  • IDF Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. FIFTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013 IMMUNE DEFICIENCY FOUNDATION Copyright 2013 by Immune Deficiency Foundation, USA. REPRINT 2015 Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficency Diseases 5th Edition This publication has been made possible through a generous grant from Baxalta Incorporated Immune Deficiency Foundation 110 West Road, Suite 300 Towson, MD 21204 800-296-4433 www.primaryimmune.org [email protected] EDITORS R. Michael Blaese, MD, Executive Editor Francisco A. Bonilla, MD, PhD Immune Deficiency Foundation Boston Children’s Hospital Towson, MD Boston, MA E. Richard Stiehm, MD M. Elizabeth Younger, CPNP, PhD University of California Los Angeles Johns Hopkins Los Angeles, CA Baltimore, MD CONTRIBUTORS Mark Ballow, MD Joseph Bellanti, MD R. Michael Blaese, MD William Blouin, MSN, ARNP, CPNP State University of New York Georgetown University Hospital Immune Deficiency Foundation Miami Children’s Hospital Buffalo, NY Washington, DC Towson, MD Miami, FL Francisco A.
    [Show full text]
  • The Pathophysiology of Paroxysmal Nocturnal Haemoglobinuria.Pdf
    The Pathophysiology of Paroxysmal Nocturnal Haemoglobinuria Richard John Kelly Submitted in accordance with the requirements for the degree of Doctor of Philosophy The University of Leeds School of Medicine January 2014 1 Jointly-Authored Publications The candidate confirms that the work submitted is his own, except where work which has formed part of jointly authored publications has been included. The contribution of the candidate and the other authors to this work has been explicitly indicated below. The candidate confirms that appropriate credit has been given within the thesis where reference has been made to the work of others. The work in Chapter 3 of the thesis has appeared in publication as follows: Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786-6792. I was responsible for designing the study, collecting and analysing the data and writing the paper. Dena Cohen and Walter Gregory performed the statistical analysis. All the other authors reviewed the paper. The work in Chapter 4 of the thesis has appeared in publication as follows: Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, Loughney A, Beauchamp J, Khursigara G, Rother RP, Chalmers E, Fyfe A, Fitzsimons E, Nakamura R, Gaya A, Risitano AM, Schubert J, Norfolk D, Simpson N, Hillmen P. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010;149:446-450. I was responsible for designing the study, collecting and analysing the data and writing the paper.
    [Show full text]
  • Our Immune System (Children's Book)
    OurOur ImmuneImmune SystemSystem A story for children with primary immunodeficiency diseases Written by IMMUNE DEFICIENCY Sara LeBien FOUNDATION A note from the author The purpose of this book is to help young children who are immune deficient to better understand their immune system. What is a “B-cell,” a “T-cell,” an “immunoglobulin” or “IgG”? They hear doctors use these words, but what do they mean? With cheerful illustrations, Our Immune System explains how a normal immune system works and what treatments may be necessary when the system is deficient. In this second edition, a description of a new treatment has been included. I hope this book will enable these children and their families to explore together the immune system, and that it will help alleviate any confusion or fears they may have. Sara LeBien This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SECOND EDITION COPYRIGHT 1990, 2007 IMMUNE DEFICIENCY FOUNDATION Copyright 2007 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Our Immune System may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 40 West Chesapeake Avenue, Suite 308, Towson, MD 21204, USA; or by telephone at 1-800-296-4433.
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • Repercussions of Inborn Errors of Immunity on Growth☆ Jornal De Pediatria, Vol
    Jornal de Pediatria ISSN: 0021-7557 ISSN: 1678-4782 Sociedade Brasileira de Pediatria Goudouris, Ekaterini Simões; Segundo, Gesmar Rodrigues Silva; Poli, Cecilia Repercussions of inborn errors of immunity on growth☆ Jornal de Pediatria, vol. 95, no. 1, Suppl., 2019, pp. S49-S58 Sociedade Brasileira de Pediatria DOI: https://doi.org/10.1016/j.jped.2018.11.006 Available in: https://www.redalyc.org/articulo.oa?id=399759353007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative J Pediatr (Rio J). 2019;95(S1):S49---S58 www.jped.com.br REVIEW ARTICLE ଝ Repercussions of inborn errors of immunity on growth a,b,∗ c,d e Ekaterini Simões Goudouris , Gesmar Rodrigues Silva Segundo , Cecilia Poli a Universidade Federal do Rio de Janeiro (UFRJ), Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro, RJ, Brazil b Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Curso de Especializac¸ão em Alergia e Imunologia Clínica, Rio de Janeiro, RJ, Brazil c Universidade Federal de Uberlândia (UFU), Faculdade de Medicina, Departamento de Pediatria, Uberlândia, MG, Brazil d Universidade Federal de Uberlândia (UFU), Hospital das Clínicas, Programa de Residência Médica em Alergia e Imunologia Pediátrica, Uberlândia, MG, Brazil e Universidad del Desarrollo,
    [Show full text]
  • Theory of an Immune System Retrovirus
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 9159-9163, December 1986 Medical Sciences Theory of an immune system retrovirus (human immunodeficiency virus/acquired immune deficiency syndrome) LEON N COOPER Physics Department and Center for Neural Science, Brown University, Providence, RI 02912 Contributed by Leon N Cooper, July 23, 1986 ABSTRACT Human immunodeficiency virus (HIV; for- initiates clonal expansion, sustained by interleukin 2 and y merly known as human T-cell lymphotropic virus type interferon. Ill/lymphadenopathy-associated virus, HTLV-Ill/LAV), the I first give a brief sketch of these events in a linked- retrovirus that infects T4-positive (helper) T cells of the interaction model in which it is assumed that antigen-specific immune system, has been implicated as the agent responsible T cells must interact with the B-cell-processed virus to for the acquired immune deficiency syndrome. In this paper, initiate clonal expansion (2). I then assume that virus-specific I contrast the growth of a "normal" virus with what I call an antibody is the major component ofimmune system response immune system retrovirus: a retrovirus that attacks the T4- that limits virus spread. As will be seen, the details of these positive T cells of the immune system. I show that remarkable assumptions do not affect the qualitative features of my interactions with other infections as well as strong virus conclusions. concentration dependence are general properties of immune Linked-Interaction Model for Clonal Expansion of Lympho- system retroviruses. Some of the consequences of these ideas cytes. Let X be the concentration of normal infecting virus are compared with observations.
    [Show full text]
  • Comprehensive Genetic Testing for Primary Immunodeficiency
     Woon and Ameratunga Allergy Asthma Clin Immunol (2016) 12:65 Allergy, Asthma & Clinical Immunology DOI 10.1186/s13223-016-0169-2 RESEARCH Open Access Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10‑year experience in Auckland, New Zealand See‑Tarn Woon and Rohan Ameratunga* Abstract Background and purpose: New Zealand is a developed geographically isolated country in the South Pacific with a population of 4.4 million. Genetic diagnosis is the standard of care for most patients with primary immunodeficiency disorders (PIDs). Methods: Since 2005, we have offered a comprehensive genetic testing service for PIDs and other immune-related disorders with a published sequence. Here we present results for this program, over the first decade, between 2005 and 2014. Results: We undertook testing in 228 index cases and 32 carriers during this time. The three most common test requests were for X-linked lymphoproliferative (XLP), tumour necrosis factor receptor associated periodic syndrome (TRAPS) and haemophagocytic lymphohistiocytosis (HLH). Of the 32 suspected XLP cases, positive diagnoses were established in only 2 patients. In contrast, genetic defects in 8 of 11 patients with suspected X-linked agammaglobu‑ linemia (XLA) were confirmed. Most XLA patients were initially identified from absence of B cells. Overall, positive diagnoses were made in about 23% of all tests requested. The diagnostic rate was lowest for several conditions with locus heterogeneity. Conclusions: Thorough clinical characterisation of patients can assist in prioritising which genes should be tested. The clinician-driven customised comprehensive genetic service has worked effectively for New Zealand. Next genera‑ tion sequencing will play an increasing role in disorders with locus heterogeneity.
    [Show full text]
  • Are Complement Deficiencies Really Rare?
    G Model MIMM-4432; No. of Pages 8 ARTICLE IN PRESS Molecular Immunology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Are complement deficiencies really rare? Overview on prevalence, ଝ clinical importance and modern diagnostic approach a,∗ b Anete Sevciovic Grumach , Michael Kirschfink a Faculty of Medicine ABC, Santo Andre, SP, Brazil b Institute of Immunology, University of Heidelberg, Heidelberg, Germany a r a t b i c s t l e i n f o r a c t Article history: Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) accord- Received 29 May 2014 ing to national and supranational registries. They are still considered rare and even of less clinical Received in revised form 18 June 2014 importance. This not only reflects (as in all PIDs) a great lack of awareness among clinicians and gen- Accepted 23 June 2014 eral practitioners but is also due to the fact that only few centers worldwide provide a comprehensive Available online xxx laboratory complement analysis. To enable early identification, our aim is to present warning signs for complement deficiencies and recommendations for diagnostic approach. The genetic deficiency of any Keywords: early component of the classical pathway (C1q, C1r/s, C2, C4) is often associated with autoimmune dis- Complement deficiencies eases whereas individuals, deficient of properdin or of the terminal pathway components (C5 to C9), are Warning signs Prevalence highly susceptible to meningococcal disease. Deficiency of C1 Inhibitor (hereditary angioedema, HAE) Meningitis results in episodic angioedema, which in a considerable number of patients with identical symptoms Infections also occurs in factor XII mutations.
    [Show full text]
  • Hereditary Angioedema: a Broad Review for Clinicians
    REVIEW ARTICLE Hereditary Angioedema A Broad Review for Clinicians Ugochukwu C. Nzeako, MD, MPH; Evangelo Frigas, MD; William J. Tremaine, MD ereditary angioedema (HAE) is an autosomal dominant disease that afflicts 1 in 10000 to 1 in 150000 persons; HAE has been reported in all races, and no sex predomi- nance has been found. It manifests as recurrent attacks of intense, massive, localized edema without concomitant pruritus, often resulting from one of several known trig- Hgers. However, attacks can occur in the absence of any identifiable initiating event. Historically, 2 types of HAE have been described. However, a variant, possibly X-linked, inherited angioedema has recently been described, and tentatively it has been named “type 3” HAE. Signs and symptoms are identical in all types of HAE. Skin and visceral organs may be involved by the typically massive local edema. The most commonly involved viscera are the respiratory and gastrointestinal sys- tems. Involvement of the upper airways can result in severe life-threatening symptoms, including the risk of asphyxiation, unless appropriate interventions are taken. Quantitative and functional analyses of C1 esterase inhibitor and complement components C4 and C1q should be performed when HAE is suspected. Acute exacerbations of the disease should be treated with intravenous purified C1 esterase inhibitor concentrate, where available. Intravenous administration of fresh frozen plasma is also useful in acute HAE; however, it occasionally exacerbates symptoms. Corti- costeroids, antihistamines, and epinephrine can be useful adjuncts but typically are not effica- cious in aborting acute attacks. Prophylactic management involves long-term use of attenuated androgens or antifibrinolytic agents.
    [Show full text]
  • Chapter 2 Agammaglobulinemia: X-Linked and Autosomal Recessive
    Agammaglobulinemia: X-Linked and Autosomal Recessive Chapter 2 Agammaglobulinemia: X-Linked and Autosomal Recessive The basic defect in both X-Linked Agammaglobulinemia and autosomal recessive agammaglobulinemia is a failure of B-lymphocyte precursors to mature into B-lymphocytes and ultimately plasma cells. Since they lack the cells that are responsible for producing immunoglobulins, these patients have severe deficiencies of all types of immunoglobulins. Definition of X-Linked Agammaglobulinemia (XLA) and Autosomal Recessive Agammaglobulinemia (ARA) X-Linked Agammaglobulinemia (XLA) was first are not coated with antibody. All of these actions described in 1952 by Dr. Ogden Bruton. This disease, prevent germs from invading body tissues where they sometimes called Bruton’s Agammaglobulinemia or may cause serious infections. (See chapter titled “The Congenital Agammaglobulinemia, was one of the first Immune System and Primary Immunodeficiency immunodeficiency diseases to be identified. XLA is an Diseases.”) inherited immunodeficiency disease in which patients The basic defect in XLA is an inability of the patient to lack the ability to produce antibodies, the proteins that produce antibodies. Antibodies are produced by make up the gamma globulin or immunoglobulin specialized cells in the body, called plasma cells. fraction of blood plasma. Plasma cells develop in an orderly sequence of steps Antibodies are an integral part of the body’s defense beginning with stem cells located in the bone marrow. mechanism against certain types of microorganisms or The stem cells give rise to immature lymphocytes, germs, like bacteria or viruses. Antibodies are important called pro-B-lymphocytes. Pro-B-lymphocytes next in the recovery from infections and protect against develop into pre-B-cells, which then give rise to getting certain infections more than once.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Primary Immunodeficiency Disorders
    ALLERGY AND IMMUNOLOGY 00954543 /98 $8.00 + .OO PRIMARY IMMUNODEFICIENCY DISORDERS Robert J. Mamlok, MD Immunodeficiency is a common thought among both patients and physicians when confronted with what is perceived as an excessive num- ber, duration, or severity of infections. Because of this, the starting point for evaluating patients for suspected immunodeficiency is based on what constitutes ”too many infections.” It generally is agreed that children with normal immune systems may have an average of 6 to 8 respiratory tract infections per year for the first decade of life. Even after a pattern of ab- normal infection is established, questions of secondary immunodeficiency should first be raised. The relatively uncommon primary immunodefi- ciency diseases are statistically dwarfed by secondary causes of recurrent infection, such as malnutrition, respiratory allergy, chronic cardiovascular, pulmonary, and renal disease, and environmental factors. On the other hand, a dizzying spiral of progress in our understanding of the genetics and immunology of primary immunodeficiency disease has resulted in improved diagnostic and therapeutic tools. Twenty-five newly recognized immunologic disease genes have been cloned in the last 5 ~ears.2~It has become arguably more important than ever for us to recognize the clinical and laboratory features of these relatively uncommon, but increasingly treatable, disorders. CLASSIFICATION The immune system has been classically divided into four separate arms: The B-cell system responsible for antibody formation, the T-cell sys- From the Division of Pediatric Allergy and Immunology, Texas Tech University Health Sci- ences Center, Lubbock, Texas PRIMARY CARE VOLUME 25 NUMBER 4 DECEMBER 1998 739 740 MAMLOK tem responsible for immune cellular regulation, the phagocytic (poly- morphonuclear and mononuclear) system and the complement (opsonic) system.
    [Show full text]